KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Goodwill & Intangibles: 2009-2024

Historic Goodwill & Intangibles for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $19.6 billion.

  • Teva Pharmaceutical Industries' Goodwill & Intangibles fell 4.78% to $19.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 billion, marking a year-over-year decrease of 4.78%. This contributed to the annual value of $19.6 billion for FY2024, which is 13.29% down from last year.
  • Teva Pharmaceutical Industries' Goodwill & Intangibles amounted to $19.6 billion in FY2024, which was down 13.29% from $22.6 billion recorded in FY2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Goodwill & Intangibles peaked at $29.5 billion during FY2020, and registered a low of $19.6 billion during FY2024.
  • Its 3-year average for Goodwill & Intangibles is $21.9 billion, with a median of $22.6 billion in 2023.
  • Data for Teva Pharmaceutical Industries' Goodwill & Intangibles shows a maximum YoY decreased of 18.10% (in 2020) over the last 5 years.
  • Over the past 5 years, Teva Pharmaceutical Industries' Goodwill & Intangibles (Yearly) stood at $29.5 billion in 2020, then declined by 15.05% to $25.1 billion in 2021, then decreased by 6.58% to $23.4 billion in 2022, then decreased by 3.77% to $22.6 billion in 2023, then fell by 13.29% to $19.6 billion in 2024.